Skip to main content
Erschienen in: Acta Neurologica Belgica 2/2017

06.04.2017 | Original Article

Potential risk factors for vitamin D levels in medium- and long-term use of antiepileptic drugs in childhood

verfasst von: Edibe Pempegül Yildiz, Şükran Poyrazoglu, Gonca Bektas, Aslı Derya Kardelen, Nur Aydinli

Erschienen in: Acta Neurologica Belgica | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Antiepileptic drugs (AED) have potential side effects through vitamin-D. Prevalence of vitamin D insufficiency and potential risk factors for the longitudinal changes of vitamin D levels compared to its baseline levels under AED treatment were investigated in this study. This retrospective study includes patients whose AED therapy were started in only autumn months, between 2000 and 2014. Detailed assessment of neurologic diagnosis and brain MRI findings, ambulatory status, types and durations of AED treatment, and baseline bone health blood tests (vitamin-D, alkaline phosphatase, calcium, and phosphate levels) were obtained on all patients. Vitamin-D deficiency was defined as 25(OH)D <20 ng/mL, while vitamin-D insufficiency was defined as 25(OH)D between 21 and 29 ng/mL. A total of 172 children (mean age 9.6 ± 4.3 years) were followed up 5.3 years in average (range 1–14.7). The mean baseline 25(OH)D level was decreased from 24.4 ± 11.6 to 19.6 ± 10.7 ng/mL at the last follow up. The mean change in the vitamin-D levels (ΔD-vitamin) was −4.8 ng/mL (p = 0.003). The rate of vitamin-D deficiency was 54% and insufficiency was 25%. Multivariate logistic regression analysis identified only long-term use of AEDs as a risk factor for the longitudinal decrease. Monotherapy with valproic acid (n = 45), carbamazepine (n = 20), levetiracetam (n = 10) and phenobarbital (n = 12) was compared with each other. There was no difference in terms of longitudinal changes in 25(OH)D levels. In the treatment of childhood epilepsy, 25(OH)D levels should be monitored, especially when long-term AED used, in order to prevent D-hypovitaminosis.
Literatur
1.
2.
Zurück zum Zitat Saggese G, Vierucci F, Boot AM, Czech-Kowalska J, Weber G, Camargo CA Jr et al (2015) Vitamin D in childhood and adolescence: an expert position statement. Eur J Pediatr 174:565–576CrossRefPubMed Saggese G, Vierucci F, Boot AM, Czech-Kowalska J, Weber G, Camargo CA Jr et al (2015) Vitamin D in childhood and adolescence: an expert position statement. Eur J Pediatr 174:565–576CrossRefPubMed
3.
Zurück zum Zitat Shellhaas RA, Joshi SM (2010) Vitamin D and bone health among children with epilepsy. Pediatr Neurol 42:385–393CrossRefPubMed Shellhaas RA, Joshi SM (2010) Vitamin D and bone health among children with epilepsy. Pediatr Neurol 42:385–393CrossRefPubMed
4.
Zurück zum Zitat Medicines and Healthcare products Regulatory Agency (MHRA), Commission on Human Medicines (CHM (2009) Drug safety advice antiepileptics: adverse effects on bone. Drug Saf Update. 2:2 Medicines and Healthcare products Regulatory Agency (MHRA), Commission on Human Medicines (CHM (2009) Drug safety advice antiepileptics: adverse effects on bone. Drug Saf Update. 2:2
5.
Zurück zum Zitat Cebeci AN, Ekici B (2014) Epilepsy treatment by sacrificing vitamin D. Expert Rev Neurother 14:481–491CrossRefPubMed Cebeci AN, Ekici B (2014) Epilepsy treatment by sacrificing vitamin D. Expert Rev Neurother 14:481–491CrossRefPubMed
6.
Zurück zum Zitat Harijan P, Khan A, Hussain N (2013) Vitamin D deficiency in children with epilepsy: do we need to detect and treat it? J Pediatr Neurosci. 8:5–10CrossRefPubMedPubMedCentral Harijan P, Khan A, Hussain N (2013) Vitamin D deficiency in children with epilepsy: do we need to detect and treat it? J Pediatr Neurosci. 8:5–10CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Shevell M, Ashwal S, Donley D, Flint J, Gingold M, Hirtz D, Majnemer A, Noetzel M, Sheth RD (2003) Quality Standards Subcommittee of the American Academy of N, Practice Committee of the Child Neurology S. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology. 60:367–380CrossRefPubMed Shevell M, Ashwal S, Donley D, Flint J, Gingold M, Hirtz D, Majnemer A, Noetzel M, Sheth RD (2003) Quality Standards Subcommittee of the American Academy of N, Practice Committee of the Child Neurology S. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology. 60:367–380CrossRefPubMed
8.
Zurück zum Zitat Erol M, Yiğit Ö, Küçük SH, Bostan Gayret Ö (2015) Vitamin D Deficiency in Children and Adolescents in Bağcılar, Istanbul. J Clin Res Pediatr Endocrinol. 7(2):134–139CrossRefPubMedPubMedCentral Erol M, Yiğit Ö, Küçük SH, Bostan Gayret Ö (2015) Vitamin D Deficiency in Children and Adolescents in Bağcılar, Istanbul. J Clin Res Pediatr Endocrinol. 7(2):134–139CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Bergqvist AG, Schall JI, Stallings VA (2007) Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia 48:66–71CrossRefPubMed Bergqvist AG, Schall JI, Stallings VA (2007) Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia 48:66–71CrossRefPubMed
11.
Zurück zum Zitat Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC (2006) Use of antiepileptic drugs and risk of fractures: case–control study among patients with epilepsy. Neurology 66:1318–1324CrossRefPubMed Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC (2006) Use of antiepileptic drugs and risk of fractures: case–control study among patients with epilepsy. Neurology 66:1318–1324CrossRefPubMed
12.
Zurück zum Zitat Baek JH, Seo YH, Kim GH, Kim MK, Eun BL (2014) Vitamin D levels in children and adolescents with antiepileptic drug treatment. Yonsei Med J 55:417–421CrossRefPubMedPubMedCentral Baek JH, Seo YH, Kim GH, Kim MK, Eun BL (2014) Vitamin D levels in children and adolescents with antiepileptic drug treatment. Yonsei Med J 55:417–421CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Lee YJ, Park KM, Kim YM, Yeon GM, Nam SO (2015) Longitudinal change of vitamin D status in children with epilepsy on antiepileptic drugs: prevalence and risk factors. Pediatr Neurol 52:153–159CrossRefPubMed Lee YJ, Park KM, Kim YM, Yeon GM, Nam SO (2015) Longitudinal change of vitamin D status in children with epilepsy on antiepileptic drugs: prevalence and risk factors. Pediatr Neurol 52:153–159CrossRefPubMed
14.
Zurück zum Zitat Nettekoven S, Strohle A, Trunz B, Wolters M, Hoffmann S, Horn R et al (2008) Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr 167:1369–1377CrossRefPubMed Nettekoven S, Strohle A, Trunz B, Wolters M, Hoffmann S, Horn R et al (2008) Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr 167:1369–1377CrossRefPubMed
15.
Zurück zum Zitat El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA (2008) Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 43:149–155CrossRefPubMed El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA (2008) Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 43:149–155CrossRefPubMed
16.
Zurück zum Zitat Bell RD, Pak CY, Zerwekh J, Barilla DE, Vasko M (1979) Effect of phenytoin on bone and vitamin D metabolism. Ann Neurol 5:374–378CrossRefPubMed Bell RD, Pak CY, Zerwekh J, Barilla DE, Vasko M (1979) Effect of phenytoin on bone and vitamin D metabolism. Ann Neurol 5:374–378CrossRefPubMed
17.
Zurück zum Zitat Mintzer S, Boppana P, Toguri J, DeSantis A (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47:510–515CrossRefPubMed Mintzer S, Boppana P, Toguri J, DeSantis A (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47:510–515CrossRefPubMed
18.
Zurück zum Zitat Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008) Drug, Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine S. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 122:398–417CrossRefPubMed Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008) Drug, Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine S. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 122:398–417CrossRefPubMed
19.
Zurück zum Zitat Cansu A, Yesilkaya E, Serdaroglu A, Hirfanoglu TL, Camurdan O, Gulbahar O et al (2008) Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 39:266–271CrossRefPubMed Cansu A, Yesilkaya E, Serdaroglu A, Hirfanoglu TL, Camurdan O, Gulbahar O et al (2008) Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol 39:266–271CrossRefPubMed
20.
Zurück zum Zitat Vanlint S, Nugent M, Durvasula S (2008) Vitamin D and people with intellectual disability. Aust Fam Phys 37:348–351 Vanlint S, Nugent M, Durvasula S (2008) Vitamin D and people with intellectual disability. Aust Fam Phys 37:348–351
21.
Zurück zum Zitat Babayigit A, Dirik E, Bober E, Cakmakci H (2006) Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 35:177–181CrossRefPubMed Babayigit A, Dirik E, Bober E, Cakmakci H (2006) Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 35:177–181CrossRefPubMed
Metadaten
Titel
Potential risk factors for vitamin D levels in medium- and long-term use of antiepileptic drugs in childhood
verfasst von
Edibe Pempegül Yildiz
Şükran Poyrazoglu
Gonca Bektas
Aslı Derya Kardelen
Nur Aydinli
Publikationsdatum
06.04.2017
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 2/2017
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-017-0775-x

Weitere Artikel der Ausgabe 2/2017

Acta Neurologica Belgica 2/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.